---
title: 'The Niche Episode 035 – Eli Lilly, Charles River, Adjuvant Capital, Everlywell, Abbott'
type: 'episode'
url: 'https://doc.social/episodes/the-niche-episode-035-eli-lilly-charles-river-adjuvant-capital-everlywell-abbott'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2021-02-22'
audio: 'unavailable — the host retired the file'
---

# The Niche Episode 035 – Eli Lilly, Charles River, Adjuvant Capital, Everlywell, Abbott

Eli Lilly bets on RIPK1, Charles River spends $875M on cell and gene therapy, Adjuvant Capital gets who’s who in backing, you can now buy an at-home COVID19 testing kit whenever you want, and Abbott does it again for the 389th time. Sponsor…

## Summary

Eli Lilly bets on RIPK1, Charles River spends $875M on cell and gene therapy, Adjuvant Capital gets who’s who in backing, you can now buy an at-home COVID19 testing kit whenever you want, and Abbott does it again for the 389th time.

**Sponsors
**[https://www.thescopemethod.com](https://www.thescopemethod.com)

**Story References
**[_https://tinyurl.com/niche-35-1_](https://tinyurl.com/niche-35-1)_
_[_https://tinyurl.com/niche-35-2_](https://tinyurl.com/niche-35-2)_
_[_https://tinyurl.com/niche-35-3_](https://tinyurl.com/niche-35-3)_
_[_https://tinyurl.com/niche-35-4_](https://tinyurl.com/niche-35-4)_
_[_https://tinyurl.com/niche-35-5_](https://tinyurl.com/niche-35-5)_

_**Music by Luke Goodson
**[https://www.soundcloud.com/lukegoodson](https://www.soundcloud.com/lukegoodson)

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.